Evenity (Romosozumab) Cost in Illinois 2026: Pricing, Insurance, and Savings Options

What Does Evenity (Romosozumab) Cost at Illinois Pharmacies in 2026?

The wholesale acquisition cost (WAC) for Evenity sits at $1,825 per monthly dose across Illinois retail and specialty pharmacies. Each dose requires two 105 mg/1.17 mL prefilled syringes administered subcutaneously, bringing the total 12-month treatment cost to roughly $21,900 before insurance or discounts 1.

Illinois pharmacy pricing tracks closely with the national average for specialty biologics. Evenity is classified as a specialty drug by most pharmacy benefit managers, which means it is typically dispensed through specialty pharmacies rather than standard retail chains. Patients picking up Evenity at a Walgreens or CVS specialty counter in Chicago, Springfield, or Peoria should expect the same $1,825 list price, though negotiated rates between insurers and pharmacies can shift the actual out-of-pocket amount significantly. The 2024 IQVIA Drug Expenditure Report noted that specialty drugs now account for over 55% of net drug spending in the United States 2. Evenity falls squarely into that category.

One important price distinction: the $1,825 figure represents the drug cost alone. Patients receiving injections in a physician's office may also face facility or administration fees billed under medical benefit codes (CPT 96372 for subcutaneous therapeutic injection), which can add $25 to $150 per visit depending on the practice setting.

Does Illinois Medicaid Cover Evenity?

Illinois Medicaid covers Evenity for patients with severe osteoporosis, but requires prior authorization (PA) before dispensing. The PA process verifies that the patient meets specific clinical criteria, typically including a confirmed diagnosis of osteoporosis with T-score at or below -2.5, documented high fracture risk, and either intolerance or inadequate response to first-line bisphosphonate therapy 3.

The Illinois Department of Healthcare and Family Services administers the Medicaid formulary through its Preferred Drug List (PDL). Evenity is not on the open formulary. Prescribers must submit documentation showing the patient qualifies under the state's step-therapy requirements. Approval timelines vary, but most PA decisions come back within 5 to 10 business days. Denials can be appealed through the standard Medicaid fair hearing process.

For dual-eligible patients (those covered by both Medicare and Medicaid), Evenity is generally billed under Medicare Part B as a physician-administered drug. Medicare Part B covers 80% of the Medicare-approved amount after the annual deductible, and Medicaid may pick up the remaining 20% coinsurance depending on the patient's specific benefit structure. The FRAME trial (N=7,180) demonstrated that romosozumab reduced new vertebral fracture risk by 73% compared to placebo at 12 months 4, data that supports PA approval when submitted alongside the patient's clinical profile.

Which Illinois Insurance Plans Cover Evenity?

Most major commercial insurers operating in Illinois provide coverage for Evenity, though tier placement and cost-sharing structures differ substantially across plans. Blue Cross Blue Shield of Illinois, Aetna, UnitedHealthcare, Cigna, and Humana all list Evenity on their specialty formularies with prior authorization requirements.

Tier placement matters. Plans that classify Evenity as a Tier 4 or Tier 5 specialty drug typically assign coinsurance of 25% to 33%, which on a $1,825 monthly cost translates to $456 to $602 per injection out of pocket before any savings programs. Some plans cap specialty drug copays at a fixed amount ($100 to $250 per fill), which significantly reduces the patient burden.

The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women states: "Romosozumab is recommended as initial therapy for postmenopausal women with osteoporosis at very high fracture risk" 5. This guideline language strengthens PA submissions because insurers reference society guidelines when adjudicating coverage requests.

Illinois marketplace plans sold through Get Covered Illinois (the state's ACA exchange) may also cover Evenity, but specialty drug cost-sharing can vary widely between bronze, silver, gold, and platinum tiers. Platinum plans generally offer lower coinsurance on specialty drugs but carry higher monthly premiums.

A practical step: before starting treatment, ask your prescriber's office to run a benefits investigation (BI) through the specialty pharmacy. This reveals the plan's specific PA criteria, expected copay, and whether the Amgen/UCB savings card can be applied.

How Does the Amgen/UCB Savings Card Work in Illinois?

The Evenity savings card, offered jointly by manufacturers Amgen and UCB, provides up to $25 to 000 in annual copay assistance for commercially insured patients. The card covers the difference between the patient's copay or coinsurance and $0 out of pocket, up to the annual cap 1.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Evenity, be a resident of the United States (including Illinois), and not be enrolled in any federal or state-funded healthcare program such as Medicare, Medicaid, TRICARE, or VA benefits. Government-insured patients are excluded from manufacturer copay cards by federal anti-kickback statute provisions.

For a patient with 30% coinsurance on a $1,825 monthly dose, the out-of-pocket cost would be $547.50 per injection. Over 12 months, that totals $6,570. The savings card would cover this entire amount, as it falls below the $25,000 annual cap. The math works for nearly all commercially insured patients: even at 50% coinsurance ($912.50/month, $10,950/year), the card covers the full year.

Activation requires a phone call or online enrollment. The specialty pharmacy then processes the card as a secondary payer at each fill. Processing is automatic after the initial setup, so patients do not need to resubmit the card monthly.

Is Compounded Romosozumab Available in Illinois?

Licensed 503A compounding pharmacies in Illinois can legally compound romosozumab preparations under federal and state compounding regulations. A 503A pharmacy operates under a patient-specific prescription, meaning a licensed prescriber must write an individual prescription for the compounded product.

This distinction is important. Compounded romosozumab is not FDA-approved and does not carry the same regulatory oversight as the branded Evenity product. The FDA's 2023 guidance on biological product compounding clarified that 503A pharmacies may compound copies of biological products that are not on the FDA's "do not compound" list, provided they meet all other requirements of Section 503A of the Federal Food, Drug, and Cosmetic Act 6.

Pricing for compounded romosozumab varies by pharmacy but has been reported at substantially lower costs than the branded product. Patients considering this route should discuss several factors with their prescriber: potency verification, sterility testing standards, and whether their insurer will cover compounded biologics (most will not). The American Association of Clinical Endocrinology (AACE) has not issued specific guidance endorsing or discouraging compounded anti-sclerostin antibodies, leaving this as a clinical judgment decision between patient and provider.

Can Illinois Patients Get Evenity Through Telehealth?

Illinois permits telehealth prescribing of Evenity by qualified providers. The Illinois Telehealth Act, as amended, allows physicians and advanced practice providers to prescribe medications, including specialty drugs, after establishing a valid provider-patient relationship through audiovisual telehealth encounters.

The practical limitation is administration. Evenity requires subcutaneous injection, and while it can technically be self-administered after proper training, many prescribers prefer in-office administration for the first several doses to monitor for injection-site reactions and ensure correct technique. A 2023 survey in the Journal of Managed Care & Specialty Pharmacy found that 68% of specialty biologic prescribers used telehealth for follow-up visits but required at least one in-person encounter for treatment initiation 7.

Illinois-based telehealth platforms and endocrinology practices can conduct the initial evaluation, order bone density testing, submit prior authorization, and coordinate with a local specialty pharmacy for dispensing. The patient then either self-injects at home or visits a nearby clinic for monthly administration.

What Clinical Evidence Supports Romosozumab's Efficacy?

Two major phase 3 trials established romosozumab's fracture-reduction efficacy. The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fracture risk by 48% and clinical fracture risk by 27% compared to alendronate alone 8.

The FRAME trial (N=7,180) compared 12 months of romosozumab to placebo, followed by 12 months of denosumab in both groups. Romosozumab reduced new vertebral fractures by 73% at 12 months and by 75% at 24 months (after both groups transitioned to denosumab) 4.

These numbers carry weight in insurance negotiations. Dr. Felicia Cosman, a lead investigator on the FRAME trial and professor of medicine at Columbia University, noted: "Romosozumab represents a true anabolic agent that both builds new bone and reduces bone resorption, a dual mechanism not seen with other osteoporosis therapies" 4.

One clinical caveat shapes Illinois prescribing patterns. The ARCH trial identified a cardiovascular safety signal: major adverse cardiac events (MACE) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over 12 months 8. This led to the FDA's boxed warning contraindicating Evenity in patients who have had a myocardial infarction or stroke within the preceding year. Illinois prescribers must document cardiovascular risk assessment before initiating therapy.

Cost-Reduction Strategies for Illinois Patients

Several approaches can lower out-of-pocket Evenity costs beyond the manufacturer savings card.

Patient assistance programs. Amgen's Safety Net Foundation provides free Evenity to uninsured or underinsured patients who meet income eligibility criteria (generally household income at or below 300% of the federal poverty level). Illinois residents can apply directly through the foundation.

Site-of-care optimization. Receiving injections at an independent physician's office rather than a hospital outpatient department can reduce administration fees by 40% to 60%. Hospital-based facilities apply facility fees (often $200 to $500 per visit) on top of the drug cost, while independent practices typically charge only the injection administration CPT code.

Specialty pharmacy shopping. While Evenity's list price is fixed, different specialty pharmacies may have varying dispensing fees, and some offer autopay discounts or waive shipping charges. AccordantHealth, BioPlus, and Optum Specialty Pharmacy all dispense Evenity in Illinois.

Sequencing considerations. Because Evenity is approved for only 12 monthly doses, the total drug exposure is time-limited compared to long-term bisphosphonate or denosumab therapy. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "The 12-month course of romosozumab should be viewed as an investment in bone formation that pays dividends when followed by anti-resorptive therapy" 5. Planning the full treatment sequence (romosozumab followed by denosumab or a bisphosphonate) before starting allows patients and providers to budget across the entire osteoporosis management timeline.

How Evenity Compares to Other Illinois Osteoporosis Treatments on Cost

Putting Evenity's $1,825/month price in context requires comparing it against other agents used for high-risk osteoporosis in Illinois.

Generic alendronate (Fosamax) costs $4 to $15 per month. Risedronate (Actonel) runs $15 to $30 monthly for generic formulations. Denosumab (Prolia) carries a list price of approximately $1,800 per injection given every six months, or $300/month equivalent 9. Teriparatide (Forteo) costs roughly $3,500 per month at list price for the daily injection pen. Abaloparatide (Tymlos) lists at approximately $3,200 per month 10.

Evenity sits in the middle of the anabolic therapy price range but above anti-resorptive agents. The distinction matters clinically: the 2020 AACE/ACE guideline recommends anabolic-first sequencing for patients at very high fracture risk, defined as those with a recent fracture, T-score below -3.0, or high FRAX probability 5. For these patients, the higher upfront cost of Evenity may be offset by the 48% relative reduction in vertebral fractures demonstrated in ARCH versus starting with a bisphosphonate alone 8.

Illinois patients weighing cost against efficacy should also factor in the treatment duration. Evenity is a fixed 12-month course. Teriparatide and abaloparatide require 18 to 24 months of daily injections. A full course of Evenity ($21,900) costs less than a full course of teriparatide ($63,000 to $84,000 at list price) or abaloparatide ($57,600 to $76,800), making it the most affordable anabolic option on a per-course basis despite the higher monthly price versus oral bisphosphonates.

Illinois-Specific Regulatory and Access Considerations

Illinois pharmacy law permits biologic substitution under the Illinois Wholesale Drug Distribution Licensing Act, but no biosimilar for romosozumab has received FDA approval as of May 2026. This means Illinois pharmacists cannot substitute a biosimilar at the pharmacy counter, and the branded Evenity product remains the only FDA-approved option.

The Illinois Department of Financial and Professional Regulation (IDFPR) oversees compounding pharmacy licensure. Any 503A pharmacy compounding romosozumab in Illinois must hold a current IDFPR compounding license and comply with USP <797> sterility standards. Patients can verify a pharmacy's license status through the IDFPR online lookup tool.

For patients in rural Illinois (areas outside Chicago, Rockford, Springfield, and Peoria metro zones), specialty pharmacy mail-order delivery is the most practical access route. Evenity ships under cold-chain conditions (2°C to 8°C) and arrives in insulated packaging with temperature monitors. Most specialty pharmacies offer free next-day delivery statewide.